{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T18:51:07Z","timestamp":1718995867658},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:00:00Z","timestamp":1383091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00393-013-1268-9","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T14:29:14Z","timestamp":1382970554000},"page":"269-276","source":"Crossref","is-referenced-by-count":5,"title":["Interleukin-6-Blockade als potenzielles therapeutisches Target bei entz\u00fcndlich-rheumatischen Erkrankungen"],"prefix":"10.1007","volume":"73","author":[{"given":"C.","family":"Iking-Konert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bartz-Bazzanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Falagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.W.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,30]]},"reference":[{"key":"1268_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/imt.11.147","volume":"4","author":"Tanaka","year":"2012","unstructured":"Tanaka T, Kishimoto T (2012) Immunotherapeutic implication of IL-6 blockade. Immunotherapy 4:87\u2013105","journal-title":"Immunotherapy"},{"key":"1268_CR2","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"Nishimoto","year":"2005","unstructured":"Nishimoto N et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132632","journal-title":"Blood"},{"key":"1268_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","volume":"95","author":"Nishimoto","year":"2000","unstructured":"Nishimoto N et al (2000) Improvement in Castleman\u2019s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56\u201361","journal-title":"Blood"},{"key":"1268_CR4","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1136\/ard.2009.126706","volume":"69","author":"Henes","year":"2010","unstructured":"Henes JC, Horger M, Guenaydin I et al (2010) Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 69(12):2217\u20132218. doi:10.1136\/ard.2009.126706 (Epub 2010 Jun 4)","journal-title":"Ann Rheum Dis"},{"key":"1268_CR5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.24899","volume":"61","author":"Tanaka","year":"2009","unstructured":"Tanaka T et al (2009) Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, Tocilizumab. Arthritis Rheum 61:1762\u20131764","journal-title":"Arthritis Rheum"},{"key":"1268_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","volume":"49","author":"Shima","year":"2010","unstructured":"Shima Y et al (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 49:2408\u20132412","journal-title":"Rheumatology"},{"key":"1268_CR7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217\u20131220. doi:10.1136\/annrheumdis-2012-202657 (Epub 2012 Dec 19)","journal-title":"Ann Rheum Dis"},{"key":"1268_CR8","first-page":"W13156","volume":"141","author":"Seitz","year":"2011","unstructured":"Seitz M et al (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:W13156","journal-title":"Swiss Med Wkly"},{"key":"1268_CR9","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/ard.2010.149351","volume":"70","author":"Beyer","year":"2011","unstructured":"Beyer C et al (2011) Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 70:1874\u20131875","journal-title":"Ann Rheum Dis"},{"key":"1268_CR10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3899\/jrheum.091185","volume":"37","author":"Hagihara","year":"2010","unstructured":"Hagihara K et al (2010) Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 37:1075\u20131076","journal-title":"J Rheumatol"},{"key":"1268_CR11","doi-asserted-by":"crossref","unstructured":"Genovese MC, Sebba A, Rubbert-Roth A et al (2013) Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years. EULAR Poster Fri 0256","DOI":"10.1136\/annrheumdis-2013-eular.1383"},{"key":"1268_CR12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","volume":"126","author":"Ito","year":"2004","unstructured":"Ito H et al (2004) A pilot randomized trial of human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s didease. Gastroenterology 126:989\u2013996","journal-title":"Gastroenterology"},{"key":"1268_CR13","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"Illei","year":"2010","unstructured":"Illei GG et al (2010) Tocilizumab in systemic lupus erythmatosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542\u2013552","journal-title":"Arthritis Rheum"},{"key":"1268_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/s10165-008-0116-2","volume":"19","author":"Nakahara","year":"2009","unstructured":"Nakahara H et al (2009) A case report of a patient with refractory adult-onset Still\u2019s disease who was successfully treated with Tocilizumab over 6 years. Mod Rheumatol 19:69\u201372","journal-title":"Mod Rheumatol"},{"key":"1268_CR15","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10067-010-1553-9","volume":"29","author":"Perdan","year":"2010","unstructured":"Perdan Pirkmajer K et al (2010) A case of refractory adult-onset Still\u2019s disease auccessfully controlled with Tocilizumab and a review of literature. Clin Rheumatol 29:1465\u20131467","journal-title":"Clin Rheumatol"},{"key":"1268_CR16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00296-010-1631-y","volume":"31","author":"Thonhofer","year":"2011","unstructured":"Thonhofer R et al (2011) Treatment of refractory adult-onset Still\u2019s disease with Tocilizumab: report of two cases and review of the literature. Rheumatol Int 31:1653\u20131656","journal-title":"Rheumatol Int"},{"key":"1268_CR17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"Kobayashi","year":"2011","unstructured":"Kobayashi M et al (2011) Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21(1):92\u201396","journal-title":"Mod Rheumatol"},{"key":"1268_CR18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/kep412","volume":"49","author":"Tanaka","year":"2010","unstructured":"Tanaka T et al (2010) Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, Tocilizumab. Rheumatology 49:824\u2013826","journal-title":"Rheumatology"},{"key":"1268_CR19","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/ard.2008.099267","volume":"68","author":"Nishida","year":"2009","unstructured":"Nishida S et al (2009) Rapid improvement of AA amyloidosis with humanized anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 68:1235\u20131236","journal-title":"Ann Rheum Dis"},{"key":"1268_CR20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s10067-009-1185-0","volume":"28","author":"Sato","year":"2009","unstructured":"Sato H et al (2009) Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 28:1113\u20131116","journal-title":"Clin Rheumatol"},{"key":"1268_CR21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s10067-010-1422-6","volume":"29","author":"Inoue","year":"2010","unstructured":"Inoue D et al (2010) Excellent therapeutic effect of Tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 29:1195\u20131197","journal-title":"Clin Rheumatol"},{"key":"1268_CR22","doi-asserted-by":"crossref","unstructured":"Okuda Y, Ohnishi M, Matoba K et al (2013) Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol","DOI":"10.1007\/s10165-013-0846-7"},{"key":"1268_CR23","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","volume":"54","author":"Okuda","year":"2006","unstructured":"Okuda Y et al (2006) Successful use of a humanized anti-interleukin-6-receptor antibody, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54(9):2997","journal-title":"Arthritis Rheum"},{"key":"1268_CR24","doi-asserted-by":"crossref","unstructured":"Iijima T, Suwabe T, Sumida K et al (2013) Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Mod Rheumatol","DOI":"10.1007\/s10165-013-0854-7"},{"key":"1268_CR25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"Narazaki","year":"2011","unstructured":"Narazaki M et al (2011) Therapeutic effect of tocilizumab on two patients with polymyosits. Rheumatology 50:1344\u20131346","journal-title":"Rheumatology"},{"key":"1268_CR26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/ken468","volume":"48","author":"Kawai","year":"2009","unstructured":"Kawai M et al (2009) Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology 48:318\u2013319","journal-title":"Rheumatology"},{"key":"1268_CR27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","volume":"22","author":"Hirano","year":"2012","unstructured":"Hirano T et al (2012) A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, Tocilizumab. Mod Rheumatol 22:298\u2013302","journal-title":"Mod Rheumatol"},{"key":"1268_CR28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.30215","volume":"63","author":"Vaitla","year":"2011","unstructured":"Vaitla PM et al (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the antibody tocilizumab. Arthritis Rheum 63:1151\u20131155","journal-title":"Arthritis Rheum"},{"key":"1268_CR29","first-page":"1","volume":"28","author":"Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schr\u00f6der A et al (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 28:1\u20134. doi:10.1001\/jamaneurol.2013.1246 (Epub ahead of print)","journal-title":"JAMA Neurol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1268-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1268-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T22:16:48Z","timestamp":1596752208000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1268-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1268-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,30]]}}}